Table 1.
patient and treatment characteristics
| entire cohort | HCC | MD | |
|---|---|---|---|
| number of patients | 55 | 27 | 28 |
| number of lesions | 70 | 36 | 34 |
| single/multiple lesions | 40/15 | 18/9 | 22/6 |
| gender (male/female) | 35/20 | 19/8 | 16/12 |
| age (median/range in years) | 64/31–83 | 63/46–83 | 67/31–80 |
| KPS (median/range in %) | 90/60–100 | 90/60–100 | 95/70–100 |
| histology (CRC/LC/BC/S/O) | – | – | 10/4/4/2/9 |
| Child-Pugh stage (A/B/C) | – | 21/5/1 | – |
| fiducials (n/%) | 42/76 | 18/67 | 24/86 |
| abdominal compression (n/%) | 26/47 | 14/52 | 12/43 |
| GTV per patient (median/range in ccm) | 14.6/0.4–204 | 15.5/1.2–204 | 13.25/0.4–98.2 |
| GTV per lesion (median/range in ccm) | 6.6/0.2–204 | 7.5/0.9–204 | 6.2/0.2–98.2 |
| PTV per patient (median/range in ccm) | 75.5/17.7–511.6 | 92.7/17.7–511.6 | 61.1/19.3–314 |
| PTV per lesion (median/range in ccm) | 59/15–512 | 61/15–512 | 51/15–314 |
| dose concept (3 × 12.5/5 × 8/other) | 28/11/16 | 16/6/5 | 12/5/9 |
| BED max (median/range) | 168.1/60.3–190 | 168.2/60.3–168.2 | 118/80.4–190 |
| actual treatment (SBRT/TACE+SBRT) | – | 12/15 | – |
HCC: hepatocellular carcinoma, MD: metastatic disease, KPS: Karnofsky performance score, CRC: colorectal cancer, LC: lung cancer, BC: breast cancer, S: sarcoma, o: other, GTV: gross tumor volume [cubic centimeters], PTV: planning target volume [cubic centimeters], BED: biologically equivalent dose, SBRT: stereotactic body radiotherapy, TACE: transarterial chemoembolization, all doses in [Gy]